Evgen Pharma Share Discussion Threads

[l0ngterm] 27/4/2018 15:14

Very true, and still happy holding here

[vatnabrekk] 27/4/2018 15:11

That's OK, when they've gone then they are gone. Then perhaps the upward movement will resume.

[nico115] 27/4/2018 15:06

Wow what a puffTwitter gang ramped and dumped Back to 13p we go : (

[l0ngterm] 27/4/2018 12:31

Rise slight drop and consolidation, hopefully progressing steady from here.

[datait] 27/4/2018 12:16

fishing over then lol

[bat5hit] 27/4/2018 10:32

Small-cap pharma undergoing a big rerate is REDX

Just hired AZN's president (and President of ABPI) Lisa Anson as their new CEO.
Also got multiple projects in the pipeline, including collaborations with AZN and Shire

[mikeh30] 27/4/2018 09:34

Nice profits. AOR for the next pharma run. £2.3m cap ;)

[miahkaysor] 27/4/2018 08:51

30p this time??

[shirley83] 27/4/2018 08:51

Some tree shake.. Unable to buy

[chesty1] 27/4/2018 08:35

Pumpy dumpy

[miahkaysor] 27/4/2018 08:30

30p coming!!!!

[moneytree1] 27/4/2018 08:22

that's me out from 12.6 glh

[spmc] 27/4/2018 08:17

It’s starting to look like positive news from the interim readout has leaked :)

[miahkaysor] 27/4/2018 08:15

30p easy today!!!!Nai.dyor.etc

[joemillion] 27/4/2018 08:12

Booooooooommmm!

[spmc] 27/4/2018 08:11

The buying is relentless, should push through 30p today :)

[sgb1969] 26/4/2018 23:06

Some good info on here today

[sgb1969] 26/4/2018 23:06

Good post timbo003
See how buying goes, 1st on the bell.hopefully a few golden tickets left

[timbo003] 26/4/2018 22:13

Not long to wait now for an initial read out.

From the last Hardman report dated December 11th....

[l0ngterm] 26/4/2018 21:57

PDT: thanks I will have a read through. As for IMM and comparisons, I don't think it is a fair comparison, due to the below.A) company approach is focused on the business, and that will take care of the share price eventually.B) the science has been researched and potential identified from multiple independent sources.D) the papers published are from multiple different sources and specialists. C) the compassionate use program has been running for a while, with one, possible more patients taking the drug for over a year. So supporting data etc. Held in advance.d) the companies approach is to partner as opposed to run phase III. So the trial design should be a lot more robust.All the above are pretty much lessons learned from where IMM dropped the ball, or that investment for me. Still trials are a risk, but ticking a lot of boxes here.Hence happy to buy.

[pdt] 26/4/2018 20:53

The cancer trial has the potential to transform metastatic breast cancer (ie one that is advanced and spreading to other parts of the body) from a death sentence to a chronic manageable condition. The interim readout due by end of June 2018 will give a good indication if it is working. The market size has been estimated at $5 billion per annum. Plus it is likely to be applicable to a whole host of other cancers.

The other trial in a type of stroke is an orphan indication with a market size of $1 billion per annum and reads out around the end of 2018. An even bigger market will be in stroke generally which hopefully Kings college will run in 2019.

It is also potentially applicable to other diseases of the brain such as Alzheimers. Have a look at this review for the potential;



For these reasons this rise may be more than a one off spike.

However, I thought IMM might do well and I got that one massively wrong. Goes to show what a risky business waiting for trial results is!

[rathean] 26/4/2018 16:49

Sold out before the close, thanks for the ride chaps, see you again at 12p gla!

[l0ngterm] 26/4/2018 16:23

Lol Welcome to the party mk..